Access to capital, government red tape among top barriers cited by biotech firms, survey finds
By Jolson LimSep. 26, 2018
Though the industry believes the federal government's flagship innovation program, SR&ED, is important and useful, all say it could use some tweaks.
A scientist working at Spartan, a biotech firm located in Ottawa, is pictured in 2017. The biotech industry in Canada is expanding, although investment issues remain, according to a recent survey. The Hill Times photograph by Sam Garcia
Access to capital remains the biggest challenge for Canada’s biotechnology sector, even as most of its companies have tapped into federal programs offered to startup companies, according to a new report released on Sept. 24.
People. Policy. Politics. This is an exclusive subscriber-only story.
CanCon Contributions & Quotas In a Digital Age As part of Heritage Canada’s review of Canadian content in a digital age, various parties are proposing changes to how digital services are regulated and taxed. Get the book
Rural Broadband: The challenges and potential solutions A guide to the problems, work done so far, the key players, and what needs to be done to get all Canadians access to broadband. Get the book
Related Policy Briefings
Agriculture Policy Briefing Short and informative analyses on policy challenges that bring background and recommendations to policymakers, journalists and the general public.